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Abstract
Antibacterial resistance in pneumococci is increasing worldwide, primarily against b-lactams and macrolides. Understanding the role
played by molecular determinants of resistance, transformation and competence in the evolution of Streptococcus pneumoniae is impor-
tant in addressing this trend. Data from the Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin
(PROTEKT) study indicate that about 40% of pneumococci display multidrug-resistant phenotypes (resistance to three or more antibiot-
ics), with highly variable prevalence rates observed in different countries. Alterations in the structure of six penicillin-binding proteins
(PBPs) have been described in S. pneumoniae (1a, 1b, 2x, 2a, 2b and 3), enabling resistance to b-lactam antibiotics. Mechanisms confer-
ring macrolide resistance include resistance mediated through the erm(B) gene, which results in macrolide–lincosamide–streptogramin B
resistance, or through the mef(A) gene, which encodes an antibiotic efflux pump. Another variant, mef(E), is also expressed in S. pneu-
moniae; both mef(A) and mef(E) variants are associated with strains belonging to serotype 14. In addition to the selection pressure
resulting from misuse of antibiotics, widespread vaccination programmes may contribute to changing pneumococcal epidemiology. Since
the introduction of the seven-valent pneumococcal conjugate vaccine (PCV7), the rate of invasive pneumococcal disease due to PCV7
serotypes has declined significantly in many countries, but some countries have reported an increase in non-PCV7 serotypes. This
phenomenon, termed ‘replacement’, is associated with certain pneumococcal serotypes or clones (e.g. serotype 19A). Whether novel
‘vaccine escape recombinant’ pneumococcal strains are emerging or changes in distribution are part of a secular cycle remains to be
determined.
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Introduction
Streptococcus pneumoniae is a common commensal of the
upper respiratory tract. Through colonization, it can lead to
local or systemic infections. Spread from the nasopharynx
can lead to local infections such as sinusitis or acute otitis
media. Aspiration can result in direct spread of S. pneumoniae
to the lungs, leading to community-acquired pneumonia
(CAP), with pleural empyema as a complication occurring in
less than 5% of CAP cases. Invasive disease can occur in 10–
15% of patients with CAP. The pneumococcus can also
spread via the blood to the brain, causing pneumococcal
meningitis. Peritonitis, arthritis and osteomyelitis are rare
manifestations of pneumococcal disease [1].
S. pneumoniae Resistance to Penicillins
The prevalence of penicillin-non-susceptible S. pneumoniae in
Europe varies: 25–50% in Spain, France, Greece and Israel;
10–25% in Portugal, Ireland, Finland and Turkey; 5–10% in
Italy; and 1–5% in the UK, Germany, Austria, Norway and
Sweden [2].
Penicillin-binding proteins (PBPs) are natural constituents
of many bacteria; they are cytoplasmic membrane-associated,
have some essential functions, and are the primary targets of
b-lactam antibiotics. Alterations in PBP structure have enabled
many bacteria to develop resistance to antibiotics. Six PBPs
have been described in S. pneumoniae: 1a, 1b, 2x, 2a, 2b and 3
[3]. Resistant strains show a mosaicism in genes encoding 2b,
2x and 1a PBPs [4,5]. This resistance is thought to be the
result of intraspecies and interspecies gene transfer [3,6],
especially from Streptococcus mitis and Streptococcus oralis [5].
Certain sequence blocks in resistant strains may differ from
those in susceptible strains by about 20%. In particular, muta-
tions in the gene encoding the penicillin-sensitive transpepti-
dase domain of PBP have been discovered [7].
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S. pneumoniae Resistance to Macrolides
S. pneumoniae resistance to macrolides is as varied as its
resistance to penicillins: 25–50% in France, Italy and Greece;
10–25% in Spain, Portugal, the UK, Germany, Poland,
Norway and Finland; and 1–5% in Latvia and Sweden [2].
The PneumoWorld surveillance study described the preva-
lence of macrolide-resistant S. pneumoniae isolated from
patients with invasive and non-invasive pneumococcal disease
in eight European countries (Austria, Belgium, France, Ger-
many, Italy, Portugal, Spain and Switzerland) from 2001 to
2003. The overall macrolide resistance (intermediate plus
resistant) in all strains was 28% (range 10.0–46.1%) [8]. A
worldwide review of the prevalence of macrolide (erythro-
mycin)-resistant S. pneumoniae reported results from 19
European countries. The reported prevalence of macrolide-
resistant (intermediate plus resistant) S. pneumoniae isolates
was similar to that described elsewhere [9].
A number of mechanisms conferring macrolide resistance
have been described. The resistance may be mediated by the
erm(B) gene, which encodes a methylase, resulting in mac-
rolide–lincosamide–streptogramin B resistance. The erm(A)
gene is found only infrequently in pneumococci. Alternatively,
resistance may be mediated by the mef(A) gene which
encodes an antibiotic efflux pump. Other mechanisms include
mutations in ribosomal RNA (23S rRNA) and ribosomal pro-
teins L4 and L22 [10,11].
In addition to the mef(A) efflux pump gene, another vari-
ant, mef(E), is expressed. These genes are 90% identical in
nucleotide sequence, and were assigned to the same class of
macrolide-resistance determinants. Initially, the mef genes
were considered to be species-specific—mef(A) was thought
to be expressed in Streptococcus pyogenes and mef(E) in
S. pneumoniae. However, mef(A) was also shown to be pres-
ent in macrolide-resistant isolates of S. pneumoniae [12,13].
mef(A) and mef(E) are carried by two similar but distinct ele-
ments, designated, respectively, Tn1207.1 and the ‘mega’
(macrolide efflux genetic assembly) element [14]. Tn1207.1 is
a defective transposon of 7.2 kb that corresponds to the left
end of the larger Tn1207.3 transposon that carries mef(A) in
S. pyogenes. The population structure of isolates carrying
Tn1207.1 is clonal, and almost all of the isolates belong to
serotype 14 and to the internationally disseminated clone
England14-9 [13,15]. The mega element, 5.5 kb in size, is
similar to Tn1207.1, but lacks the region upstream of mef.
The mega element can be found inserted at different chro-
mosomal sites in strains belonging to different serotypes and
clonal groups [14]. In recent years, the presence of both
the erm(B) and the mef(E) or mef(A) genes in S. pneumoniae
clinical isolates has been increasingly recognized, but they are
more prevalent in Asian countries than in Europe and the
USA [16].
Global Genotype Distribution in
Macrolide-resistant Isolates
The Prospective Resistant Organism Tracking and Epidemiol-
ogy for the Ketolide Telithromycin (PROTEKT) study is a
global, longitudinal, international surveillance study designed
primarily to compare the antibacterial activity of the ketolide
telithromycin with other antibacterials. The study, conducted
in 38 countries, tracks antibacterial resistance and changes in
resistance over time using genotyping and other methods.
Year 5 PROTEKT data (2003–2004) showed that the rate of
erythromycin resistance in S. pneumoniae isolates from
patients with community-acquired respiratory tract infections
was 37.2% [17]. The most common resistance genotype was
erm(B), which was present in 55.0% of isolates, and the sec-
ond most common was the mef(A) genotype, present in
30.6%. Interestingly, 12.0% of isolates exhibited both erm(B)
and mef(A) genotypes, indicating dual resistance mechanisms.
This dual genotype was more prevalent in the group of
patients aged <2 years [17].
This variation in genotype may be understood in the con-
text of Darwinian natural selection and fitness. If differences
in individual genotypes affect fitness, then the frequencies of
the genotypes will change over generations. The ability of an
organism of a certain genotype, e.g. that of multidrug-resis-
tant serotype 19A, to reproduce is usually related to the
proportion of the organism’s genes in all the genes of the
next generation. It stands to reason that a genotype with a
higher fitness for survival will then be naturally selected by
evolution.
Factors Associated with Pneumococcal
Evolution
Multiple factors may have aided the evolution and survival of
various pneumococcal serotypes. The selection pressure
resulting from human misuse of antibiotics is obvious. The
total usage of antibiotics in Europe has increased; France had
the highest rate, at 32.2 defined daily doses/1000 inhabitants/
day. The Netherlands had the lowest rate, at 10 defined daily
doses/1000 inhabitants/day [18]. Low compliance, easy avail-
ability of over-the-counter medication in some countries
and, in many cases, use of the wrong class of antibiotics for
a particular disease have all contributed to this diversity.
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Since the introduction of PCV7, the rate of invasive pneu-
mococcal disease (IPD) among vaccinated children aged
<5 years has decreased significantly in many countries. In
some countries where PCV7 is widely used, an increase (rel-
ative and absolute) of non-PCV7 vaccine serotypes has been
observed. This phenomenon has been termed ‘replacement’,
and the accuracy of this designation is a matter of ongoing
debate. The ‘replacement phenomenon’ has been associated
with certain pneumococcal serotypes or certain clones, e.g.
serotype 19A.
PCV7 was introduced into the routine childhood vacci-
nation schedule for Alaskan children in January 2001 [19].
Between 2001 and 2004–2006, IPD due to PCV7 sero-
types declined by 97% in Alaskan children aged <2 years.
Between 2001–2003 and 2004–2006, the rate of non-
PCV7-type IPD increased by 130% in Alaskan native chil-
dren aged <2 years. IPD due to serotype 19A accounted
for 29% of cases [19].
However, another study of a high-risk population provided
different results [20]. Following PCV7 introduction among
White Mountain Apache people, the rate of IPD due to
PCV7 serotypes decreased by 92% in children aged <5 years.
No commensurate increase in the rate of non-PCV7-sero-
type IPD was observed and the prevalence of serotype 19A
did not change after PCV7 introduction in this population
[20]. A study from Korea demonstrated that the expansion
of a multidrug-resistant serotype 19A clone occurred before
the introduction of PCV7 in that country [21].
The questions that should be answered by any scientist in
the field are as follows: if there are multiple selection factors,
how can a single factor be identified as causative? Addition-
ally, if vaccine strains increase selection pressure, why should
there be an increase in a single non-vaccine serotype and
not an equal increase in all non-vaccine serotypes? Is it possi-
ble to differentiate between a selective pressure-induced
change in pneumococcal serotype distribution and a change
in distribution that is part of a secular cycle that has been
observed for many years?
Clearly, the differences between pneumococcal serotypes
in their potential to colonize the nasopharynx, to acquire
resistance genes or to cause invasive disease may contribute
to the observation of a changing pneumococcal epidemiol-
ogy. A particular serotype may rank high in the list of inva-
sive serotypes simply because children are very frequently
exposed to that serotype and occasionally develop disease,
not because that serotype is particularly invasive. Conversely,
a highly invasive serotype may be much more likely to cause
disease after acquisition, but if it is infrequent in the popula-
tion, it will appear to be less invasive simply because it is
lower in the rank order of serotypes causing disease [22].
It is well known that in infants and young children, particu-
lar serotypes/groups, e.g. 3, 6A, 6B, 9V, 14, 15, 19A, 19F, 21,
23F and 35, colonize the nasopharynx. Serotype distribution
among nasopharyngeal carriage isolates varies slightly by
country, age group and type of cohort. Europe and the USA
show similar serotype distributions, with minor differences
in several serotypes [1]. Some of these serotypes, notably
6A, 6B, 9V, 14, 19A, 19F and 23F, also frequently show
resistance [8,21,23].
In addition, there are no serotypes that only rarely colo-
nize young children and often show resistance. This provides
support for the assumption that resistance in pneumococci
may be closely related to the habitat of the nasopharynx.
However, some of the common colonizing serotypes, such
as 3, 15A/B, 21, 23A and 35F/B, show resistance infrequently;
there must be other factors that hinder the acquisition of
resistance genes in these strains. Subinhibitory concentra-
tions of antibiotics, which may occur in the nasopharynx,
could possibly explain the generation of resistant strains in
this habitat and the selection favouring the long-term-colo-
nizing serotypes. Studies of macrolides with long elimination
half-lives that may allow subinhibitory epithelial lining fluid
concentrations to persist over a period of several weeks
after antibiotic treatment have demonstrated that 85% (51/
60) of children treated with a long elimination half-life mac-
rolide were colonized by macrolide-resistant organisms
6 weeks after antibiotic treatment [24].
An important distinction between penicillin-resistance
determinants and macrolide-resistance determinants in the
pneumococcal genome is that the PBP genes are fixed on
the bacterial chromosome, whereas macrolide-resistance
determinants are found on mobile genetic elements (transpo-
sons). The distance on the genome between the genes
encoding important PBPs such as 2x and 1a is small, making
a recombination event less likely. Moreover, these genes are
found in the pneumococcal genome near the capsular locus,
which may further explain the association between PBP alter-
ations and certain pneumococcal serotypes.
Mechanisms of Adaptation in S. pneumoniae
The serotype distribution of S. pneumoniae colonizing the
nasopharynx has undergone a shift since the use of PCV7
became routine in the USA. Serotypes not covered by the
vaccine have increased with regard to both colonization and
association with clinical illness. The increase in serotype 19A
in the USA (and other countries since at least 1990) may
partially be explained by expansion of a genotype that was
circulating prior to vaccine implementation, and also by the
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emergence of a novel ‘vaccine escape recombinant’ pneumo-
coccal strain. A recent study from the USA found strains
with a genotype that previously was only associated with
vaccine serotype 4, but now expresses a non-PCV7 sero-
type 19A capsule; this may occur through recombination in
naturally transformable clones [25]. The new serotypes
(serotype switching) thus acquire a non-PCV7 capsule. How-
ever, one may argue that no molecular work can prove the
causal relation between an alteration in a capsular type and
the introduction of a vaccine.
The Role of Competence
S. pneumoniae shares the property of natural transformation
with at least 40 bacterial species. Competence is, in part,
induced by the competence-stimulating peptide (CSP), which
enables the organism to take up and process DNA [26–28].
As described above, among the serotypes often colonizing
the nasopharynx, serotype 3 is the most exceptional, as it
only rarely shows resistance. A study published by Hsieh
et al. compared competence among various serotypes of
pneumococci. The transformation capabilities of CSP1 and
CSP2 were also studied. Serotype 3 showed a relatively low
competence level when compared with other pneumococcal
serotypes, e.g. 14 and 19F [23]. One may assume that the
presence of both adherence factors that support colonization
and competence factors that facilitate the uptake of foreign
DNA may be a prerequisite for the high level of resistance
in a particular serotype.
Consequences of Competence and
Adaptation
Genetic transformation seems to play a critical role in the
evolution of S. pneumoniae. This mechanism has been impli-
cated in various events, including the assembly of mosaic
antibiotic-resistant genes [28,29]. The genetic versatility of
S. pneumoniae results in multiple patterns of antibiotic resis-
tance. It is of concern that about 40% of pneumococci dis-
play multidrug-resistance phenotypes, with highly variable
prevalence rates seen in different countries. Data from the
PROTEKT study demonstrated that, worldwide, in penicillin-
resistant isolates, co-resistance to macrolides is found in 72–
75% of isolates, co-resistance to tetracycline in 65–72%, and
co-resistance to co-trimoxazole in 69–74% [30]. Data from
the PROTEKT study (1999–2002) also showed that the prev-
alence of multidrug-resistant pneumococci was highest in
Asia, in particular China (97.3% of isolates) and Taiwan
(92.7%). Lower rates were reported from the UK (3.8%) and
Russia (4.6%) [30].
Conclusions
Antibacterial resistance in pneumococci is increasing world-
wide, primarily to b-lactams and macrolides. In European
countries such as France and Spain, as many as 40% of pneu-
mococci display multidrug resistance. Our understanding of
the molecular determinants of resistance, transformation and
competence is increasing and will help us to address this
disturbing trend.
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